{"commentary":{"count":32,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":21,"youtube":5,"podcast":5,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04090710\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CYTOSHRINK","nct_id":"NCT04090710","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cytoshrink-nct04090710. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"CYTOSHRINK","arms":[{"description":"induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for cycles 1-4 followed by maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.","label":"Standard of Care I/N alone","type":"ACTIVE_COMPARATOR"},{"description":"induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for one cycle, followed by SBRT to the primary disease in-situ, prior to cycle 2-4 of I/N. Patients randomized to SBRT will undergo radiation planning during the first cycle of I/N to their primary kidney mass, and then the radiation will be delivered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day over 1.5 weeks. Approximately one week following completion of SBRT, patients will start cycle 2 of immunotherapy as per standard of care. The total time elapsed between the start of cycle 1 and 2 of I/N should be no more than 6 weeks. After completion of up to four cycles of I/N, patients will proceed to standard of care maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.","label":"Standard of Care I/N plus primary disease SBRT","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb","Hamilton Health Sciences Corporation"],"completion_date":{"date":"2026-06-30","type":"ACTUAL"},"conditions":["Metastatic Renal Cell Carcinoma"],"enrollment":{"count":66,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Ipilimumab/ Nivolumab","type":"DRUG"},{"name":"SBRT + Ipilimumab/Nivolumab","type":"RADIATION"}],"last_update":"2026-08-28","lead_sponsor":"Ontario Clinical Oncology Group (OCOG)","official_title":"Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2026-04-23","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression free survival (PFS)","timeFrame":"2 years"}],"references":[],"start_date":{"date":"2020-01-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer","url":"https://clinicaltrials.gov/study/NCT04090710"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cytoshrink-nct04090710"}